Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Canagliflozin, an SGLT2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats.

Kimura Y, Kuno A, Tanno M, Sato T, Ohno K, Shibata S, Nakata K, Sugawara H, Abe K, Igaki Y, Yano T, Miki T, Miura T.

J Diabetes Investig. 2019 Jan 21. doi: 10.1111/jdi.13009. [Epub ahead of print]

2.

Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and anti-oxidants in diabetic rats.

Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M, Yano T, Nakata K, Kimura Y, Abe K, Ohwada W, Miura T.

J Pharmacol Exp Ther. 2018 Dec 14. pii: jpet.118.253666. doi: 10.1124/jpet.118.253666. [Epub ahead of print]

3.

Accuracy of flash glucose monitoring in insulin-treated patients with type 2 diabetes.

Sato T, Oshima H, Nakata K, Kimura Y, Yano T, Furuhashi M, Tanno M, Miki T, Miura T.

J Diabetes Investig. 2018 Oct 11. doi: 10.1111/jdi.12954. [Epub ahead of print]

4.

Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.

Mizuno M, Kuno A, Yano T, Miki T, Oshima H, Sato T, Nakata K, Kimura Y, Tanno M, Miura T.

Physiol Rep. 2018 Jun;6(12):e13741. doi: 10.14814/phy2.13741.

5.

Inhibitory Effects of Baicalein Derived from Japanese Traditional Herbal Medicine on SN-38 Glucuronidation.

Satoh T, Igarashi A, Tanno M, Yamada K, Takahashi-Suzuki N, Watanabe K.

J Pharm Pharm Sci. 2018;21(1):195-206. doi: 10.18433/jpps29783.

6.

Translational regulation by miR-301b upregulates AMP deaminase in diabetic hearts.

Tatekoshi Y, Tanno M, Kouzu H, Abe K, Miki T, Kuno A, Yano T, Ishikawa S, Ohwada W, Sato T, Niinuma T, Suzuki H, Miura T.

J Mol Cell Cardiol. 2018 Jun;119:138-146. doi: 10.1016/j.yjmcc.2018.05.003. Epub 2018 May 4.

PMID:
29733818
7.

Does p53 Inhibition Suppress Myocardial Ischemia-Reperfusion Injury?

Yano T, Abe K, Tanno M, Miki T, Kuno A, Miura T, Steenbergen C.

J Cardiovasc Pharmacol Ther. 2018 Jul;23(4):350-357. doi: 10.1177/1074248418763612. Epub 2018 Mar 19.

8.

Distinct impacts of sleep-disordered breathing on glycemic variability in patients with and without diabetes mellitus.

Nakata K, Miki T, Tanno M, Ohnishi H, Yano T, Muranaka A, Sato T, Oshima H, Tatekoshi Y, Mizuno M, Abe K, Miura T.

PLoS One. 2017 Dec 19;12(12):e0188689. doi: 10.1371/journal.pone.0188689. eCollection 2017.

9.

Diabetes increases the susceptibility to acute kidney injury after myocardial infarction through augmented activation of renal Toll-like receptors in rats.

Ohno K, Kuno A, Murase H, Muratsubaki S, Miki T, Tanno M, Yano T, Ishikawa S, Yamashita T, Miura T.

Am J Physiol Heart Circ Physiol. 2017 Dec 1;313(6):H1130-H1142. doi: 10.1152/ajpheart.00205.2017. Epub 2017 Aug 19.

10.

[A Case of Amusia Following Right Temporal Subcortical Hemorrhage].

Nagayoshi N, Arai T, Tanno M, Watanabe M, Suzuki T, Akasaki Y, Murayama Y.

Brain Nerve. 2017 Jul;69(7):862-867. doi: 10.11477/mf.1416200832. Japanese.

PMID:
28740002
11.

Suppressed autophagic response underlies augmentation of renal ischemia/reperfusion injury by type 2 diabetes.

Muratsubaki S, Kuno A, Tanno M, Miki T, Yano T, Sugawara H, Shibata S, Abe K, Ishikawa S, Ohno K, Kimura Y, Tatekoshi Y, Nakata K, Ohwada W, Mizuno M, Miura T.

Sci Rep. 2017 Jul 13;7(1):5311. doi: 10.1038/s41598-017-05667-5.

12.

Effect of sodium-glucose co-transporter-2 inhibitors on impaired ventricular repolarization in people with Type 2 diabetes.

Sato T, Miki T, Ohnishi H, Yamashita T, Takada A, Yano T, Tanno M, Tsuchida A, Miura T.

Diabet Med. 2017 Oct;34(10):1367-1371. doi: 10.1111/dme.13424. Epub 2017 Aug 3.

PMID:
28703863
13.

Suppression of autophagic flux contributes to cardiomyocyte death by activation of necroptotic pathways.

Ogasawara M, Yano T, Tanno M, Abe K, Ishikawa S, Miki T, Kuno A, Tobisawa T, Muratsubaki S, Ohno K, Tatekoshi Y, Nakata K, Ohwada W, Miura T.

J Mol Cell Cardiol. 2017 Jul;108:203-213. doi: 10.1016/j.yjmcc.2017.06.008. Epub 2017 Jun 21.

PMID:
28647341
14.

Insufficient activation of Akt upon reperfusion because of its novel modification by reduced PP2A-B55α contributes to enlargement of infarct size by chronic kidney disease.

Tobisawa T, Yano T, Tanno M, Miki T, Kuno A, Kimura Y, Ishikawa S, Kouzu H, Nishizawa K, Yoshida H, Miura T.

Basic Res Cardiol. 2017 May;112(3):31. doi: 10.1007/s00395-017-0621-6. Epub 2017 Apr 18.

PMID:
28421341
15.

Distinct risk factors of atrial fibrillation in patients with and without coronary artery disease: a cross-sectional analysis of the BOREAS-CAG Registry data.

Murakami N, Tanno M, Kokubu N, Nishida J, Nagano N, Ohnishi H, Akasaka H, Miki T, Tsuchihashi K, Miura T.

Open Heart. 2017 Jan 16;4(1):e000573. doi: 10.1136/openhrt-2016-000573. eCollection 2017.

16.

Esterification of 24S-OHC induces formation of atypical lipid droplet-like structures, leading to neuronal cell death.

Takabe W, Urano Y, Vo DH, Shibuya K, Tanno M, Kitagishi H, Fujimoto T, Noguchi N.

J Lipid Res. 2016 Nov;57(11):2005-2014. Epub 2016 Sep 19.

17.

Chronic Treatment With an Erythropoietin Receptor Ligand Prevents Chronic Kidney Disease-Induced Enlargement of Myocardial Infarct Size.

Nishizawa K, Yano T, Tanno M, Miki T, Kuno A, Tobisawa T, Ogasawara M, Muratsubaki S, Ohno K, Ishikawa S, Miura T.

Hypertension. 2016 Sep;68(3):697-706. doi: 10.1161/HYPERTENSIONAHA.116.07480. Epub 2016 Jul 25.

PMID:
27456523
18.

Clinical impact of myocardial mTORC1 activation in nonischemic dilated cardiomyopathy.

Yano T, Shimoshige S, Miki T, Tanno M, Mochizuki A, Fujito T, Yuda S, Muranaka A, Ogasawara M, Hashimoto A, Tsuchihashi K, Miura T.

J Mol Cell Cardiol. 2016 Feb;91:6-9. doi: 10.1016/j.yjmcc.2015.12.022. Epub 2015 Dec 29.

PMID:
26739211
19.

Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats.

Murase H, Kuno A, Miki T, Tanno M, Yano T, Kouzu H, Ishikawa S, Tobisawa T, Ogasawara M, Nishizawa K, Miura T.

Cardiovasc Diabetol. 2015 Aug 11;14:103. doi: 10.1186/s12933-015-0264-6.

20.

The effects of resveratrol and SIRT1 activation on dystrophic cardiomyopathy.

Kuno A, Tanno M, Horio Y.

Ann N Y Acad Sci. 2015 Aug;1348(1):46-54. doi: 10.1111/nyas.12812. Epub 2015 Jun 24. Review.

PMID:
26109180
21.

Excessive degradation of adenine nucleotides by up-regulated AMP deaminase underlies afterload-induced diastolic dysfunction in the type 2 diabetic heart.

Kouzu H, Miki T, Tanno M, Kuno A, Yano T, Itoh T, Sato T, Sunaga D, Murase H, Tobisawa T, Ogasawara M, Ishikawa S, Miura T.

J Mol Cell Cardiol. 2015 Mar;80:136-45. doi: 10.1016/j.yjmcc.2015.01.004. Epub 2015 Jan 16.

PMID:
25599963
22.

Accelerated recovery of mitochondrial membrane potential by GSK-3β inactivation affords cardiomyocytes protection from oxidant-induced necrosis.

Sunaga D, Tanno M, Kuno A, Ishikawa S, Ogasawara M, Yano T, Miki T, Miura T.

PLoS One. 2014 Nov 12;9(11):e112529. doi: 10.1371/journal.pone.0112529. eCollection 2014.

23.

Diurnal variations of blood glucose by continuous blood glucose monitoring in peritoneal dialysis patients with diabetes.

Mori T, Chida M, Oba I, Koizumi K, Furusho M, Tanno M, Naganuma E, Ito S.

Adv Perit Dial. 2014;30:54-9.

PMID:
25338422
24.

Translocation of glycogen synthase kinase-3β (GSK-3β), a trigger of permeability transition, is kinase activity-dependent and mediated by interaction with voltage-dependent anion channel 2 (VDAC2).

Tanno M, Kuno A, Ishikawa S, Miki T, Kouzu H, Yano T, Murase H, Tobisawa T, Ogasawara M, Horio Y, Miura T.

J Biol Chem. 2014 Oct 17;289(42):29285-96. doi: 10.1074/jbc.M114.563924. Epub 2014 Sep 3.

25.

Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?

Miki T, Tobisawa T, Sato T, Tanno M, Yano T, Akasaka H, Kuno A, Ogasawara M, Murase H, Saitoh S, Miura T.

Cardiovasc Diabetol. 2014 Aug 21;13:125. doi: 10.1186/s12933-014-0125-8.

26.

Type 2 diabetes induces subendocardium-predominant reduction in transient outward K+ current with downregulation of Kv4.2 and KChIP2.

Sato T, Kobayashi T, Kuno A, Miki T, Tanno M, Kouzu H, Itoh T, Ishikawa S, Kojima T, Miura T, Tohse N.

Am J Physiol Heart Circ Physiol. 2014 Apr 1;306(7):H1054-65. doi: 10.1152/ajpheart.00414.2013. Epub 2014 Jan 31.

27.

Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.

Mori T, Oba I, Koizumi K, Kodama M, Shimanuki M, Tanno M, Chida M, Saito M, Kiyomoto H, Miyazaki M, Ogawa S, Sato H, Ito S.

Adv Perit Dial. 2013;29:33-7.

PMID:
24344488
28.

[Effect of different preoperative rehydration on sugar metabolism; comparison between Arginaid Water and OS-1].

Tanno M, Fukushima H, Tanaka Y, Ohara S.

Masui. 2013 Aug;62(8):910-5. Japanese.

PMID:
23984563
29.

Respiratory bronchiolitis and lung carcinoma.

Yamada Y, Terada J, Tatsumi K, Kono C, Tanno M, Takemura T, Yamaguchi T.

Respir Investig. 2013 Sep;51(3):184-90. doi: 10.1016/j.resinv.2013.03.003. Epub 2013 Jun 7.

PMID:
23978645
30.

Surgical resection of cystic intraductal papillary adenocarcinoma of the bile duct: report of a case.

Shimoda T, Yoshida H, Hirakata A, Makino H, Yokoyama T, Maruyama H, Ueda J, Tanno M, Naito Z, Uchida E.

J Nippon Med Sch. 2013;80(3):234-9.

31.

Resveratrol improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of p300 protein.

Kuno A, Hori YS, Hosoda R, Tanno M, Miura T, Shimamoto K, Horio Y.

J Biol Chem. 2013 Feb 22;288(8):5963-72. doi: 10.1074/jbc.M112.392050. Epub 2013 Jan 6.

32.

Histopathology of the pancreas in fulminant type 1 diabetes after 23-year follow-up: a case report.

Sato T, Miki T, Murakami N, Hirohashi Y, Kouzu H, Furuhashi M, Tanno M, Yuda S, Saitoh S, Hasegawa T, Miura T.

Pathol Int. 2012 Dec;62(12):827-9. doi: 10.1111/pin.12017. No abstract available.

PMID:
23252873
33.

Reversal of metabolic shift in post-infarct-remodelled hearts: possible novel therapeutic approach.

Tanno M, Kuno A.

Cardiovasc Res. 2013 Feb 1;97(2):195-6. doi: 10.1093/cvr/cvs364. Epub 2012 Dec 11. No abstract available.

PMID:
23234681
34.

Cytoprotective regulation of the mitochondrial permeability transition pore is impaired in type 2 diabetic Goto-Kakizaki rat hearts.

Itoh T, Kouzu H, Miki T, Tanno M, Kuno A, Sato T, Sunaga D, Murase H, Miura T.

J Mol Cell Cardiol. 2012 Dec;53(6):870-9. doi: 10.1016/j.yjmcc.2012.10.001. Epub 2012 Oct 12.

PMID:
23063677
35.

 Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects.

Reggiardo MV, Fay F, Tanno M, García-Camacho G, Bottaso O, Ferretti S, Godoy A, Guerrita C, Paez M, Tanno F, Ruffinengo O, Benetti S, García Borrás SE, Rossi MC, Vorobioff J, Bessone F, Tanno H.

Ann Hepatol. 2012 Sep-Oct;11(5):658-66.

36.

Role of ER stress in ventricular contractile dysfunction in type 2 diabetes.

Takada A, Miki T, Kuno A, Kouzu H, Sunaga D, Itoh T, Tanno M, Yano T, Sato T, Ishikawa S, Miura T.

PLoS One. 2012;7(6):e39893. doi: 10.1371/journal.pone.0039893. Epub 2012 Jun 29.

37.

Clinicopathological study of a case of heart transplantation.

Tanno M, Tanno N, Hayakawa K, Seki K.

J Nippon Med Sch. 2012;79(2):102-3. No abstract available.

38.

Emerging beneficial roles of sirtuins in heart failure.

Tanno M, Kuno A, Horio Y, Miura T.

Basic Res Cardiol. 2012 Jul;107(4):273. doi: 10.1007/s00395-012-0273-5. Epub 2012 May 24. Review.

39.

Role of connexin-43 in protective PI3K-Akt-GSK-3β signaling in cardiomyocytes.

Ishikawa S, Kuno A, Tanno M, Miki T, Kouzu H, Itoh T, Sato T, Sunaga D, Murase H, Miura T.

Am J Physiol Heart Circ Physiol. 2012 Jun 15;302(12):H2536-44. doi: 10.1152/ajpheart.00940.2011. Epub 2012 Apr 13.

40.

The mPTP and its regulatory proteins: final common targets of signalling pathways for protection against necrosis.

Miura T, Tanno M.

Cardiovasc Res. 2012 May 1;94(2):181-9. doi: 10.1093/cvr/cvr302. Epub 2011 Nov 9.

PMID:
22072634
41.

Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.

Hori YS, Kuno A, Hosoda R, Tanno M, Miura T, Shimamoto K, Horio Y.

J Pharmacol Exp Ther. 2011 Sep;338(3):784-94. doi: 10.1124/jpet.111.183210. Epub 2011 Jun 7.

PMID:
21652783
42.

Sesquarterpenes (C35 terpenes) biosynthesized via the cyclization of a linear C35 isoprenoid by a tetraprenyl-β-curcumene synthase and a tetraprenyl-β-curcumene cyclase: identification of a new terpene cyclase.

Sato T, Yoshida S, Hoshino H, Tanno M, Nakajima M, Hoshino T.

J Am Chem Soc. 2011 Jun 29;133(25):9734-7. doi: 10.1021/ja203779h. Epub 2011 Jun 7.

PMID:
21627333
43.

Nitrate removal efficiency and bacterial community dynamics in denitrification processes using poly (L-lactic acid) as the solid substrate.

Takahashi M, Yamada T, Tanno M, Tsuji H, Hiraishi A.

Microbes Environ. 2011;26(3):212-9. Epub 2011 May 11.

44.

Malignant granular cell tumor in the gluteal region with unusual pathologic features.

Suzuki S, Maeda S, Sasajima K, Yoshida H, Yokoyama T, Maruyama H, Matsutani T, Liu A, Hosone M, Tanno M, Uchida E.

Int Surg. 2010 Oct-Dec;95(4):360-5.

PMID:
21309422
45.

Hypertensive hypertrophied myocardium is vulnerable to infarction and refractory to erythropoietin-induced protection.

Yano T, Miki T, Tanno M, Kuno A, Itoh T, Takada A, Sato T, Kouzu H, Shimamoto K, Miura T.

Hypertension. 2011 Jan;57(1):110-5. doi: 10.1161/HYPERTENSIONAHA.110.158469. Epub 2010 Nov 8.

PMID:
21060000
46.

Oligonol, an oligomerized lychee fruit-derived polyphenol, activates the Ras/Raf-1/MEK1/2 cascade independent of the IL-6 signaling pathway in rat primary adipocytes.

Ogasawara J, Kitadate K, Nishioka H, Fujii H, Sakurai T, Kizaki T, Izawa T, Ishida H, Tanno M, Ohno H.

Biochem Biophys Res Commun. 2010 Nov 19;402(3):554-9. doi: 10.1016/j.bbrc.2010.10.082. Epub 2010 Oct 23.

PMID:
20974109
47.

Erythropoietin (EPO) affords more potent cardioprotection by activation of distinct signaling to mitochondrial kinases compared with carbamylated EPO.

Sato T, Tanno M, Miki T, Yano T, Sato T, Shimamoto K, Miura T.

Cardiovasc Drugs Ther. 2010 Dec;24(5-6):401-8. doi: 10.1007/s10557-010-6265-5.

PMID:
20953685
48.

Roles of phospho-GSK-3β in myocardial protection afforded by activation of the mitochondrial K ATP channel.

Terashima Y, Sato T, Yano T, Maas O, Itoh T, Miki T, Tanno M, Kuno A, Shimamoto K, Miura T.

J Mol Cell Cardiol. 2010 Nov;49(5):762-70. doi: 10.1016/j.yjmcc.2010.08.001. Epub 2010 Aug 6.

PMID:
20692265
49.

Mitochondrial kinase signalling pathways in myocardial protection from ischaemia/reperfusion-induced necrosis.

Miura T, Tanno M, Sato T.

Cardiovasc Res. 2010 Oct 1;88(1):7-15. doi: 10.1093/cvr/cvq206. Epub 2010 Jun 18. Review.

PMID:
20562423
50.

Mitochondria and GSK-3beta in cardioprotection against ischemia/reperfusion injury.

Miura T, Tanno M.

Cardiovasc Drugs Ther. 2010 Jun;24(3):255-63. doi: 10.1007/s10557-010-6234-z. Review.

PMID:
20490903

Supplemental Content

Support Center